Orqis tests CHF recovery system in US trial
This article was originally published in Clinica
The US FDA has given Orqis Medical the green light to conduct a pivotal clinical trial of its catheter-based cardiac recovery system for treating congestive heart failure (CHF). The MOMENTUM trial will test the company's system, called Cancion, in up to 200 CHF patients at 40 centres. Cancion is the first therapy for CHF based on continuous aortic blood flow augmentation to the descending aorta, claims the Lake Forest, California firm. It is designed to allow the heart to rest while it recovers from an acute decompensation event.